Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
A model for the immune clearance and destruction of homologous erythrocytes has been further explored. In this model, every IgM anti-erythrocyte antibody molecule in an antibody preparation was shown to fix Cl. About 2000 IgG antibody molecules were required to form a Cl-fixing site on the guinea pig erythrocyte surface. 60 IgM complement-fixing sites per erythrocyte were required for the immune clearance of IgM-sensitized erythrocytes. This number of sites could be detected by a direct agglutination test. 1.4 complement-fixing sites were required for immune clearance of IgG-sensitized cells, a number of molecules which could not be detected by direct agglutination. This number could, however, be detected with the use of a Coombs antiglobulin reagent. Depletion of the late components of complement (C3-9) with cobra venom was associated with the loss of ability to clear IgM-sensitized cells and a marked deficit in the ability to clear IgG-coated cells. Thus, late (C3-9) components of complement as well as an early component (C4) were required for normal clearance of sensitized erythrocytes. There was no evidence that activation of the alternate pathway of complement action could lead to accelerated erythrocyte clearance. In vitro incubation of IgG and IgM-sensitized erythrocytes in fresh serum led to deposition of C3 and C4 on the erythrocyte surface. IgM-sensitized cells treated in this way had a normal survival. IgM-sensitized cells also were shown to remain Coombs positive after their release from the liver. The evidence suggests that the interaction of an IgM site with fresh serum in vitro and in vivo leads to formation of a site which allows for sequestration of cells in the liver. With continued exposure to serum components, this site is destroyed or inactivated. This serum-dependent inactivation is complement-dependent as shown by the use of EDTA-treated and C4-deficient serum. IgG complement-fixing sites are only partially inactivated by incubation in fresh serum, further emphasizing the differences in the biologic activity of IgM and IgG antibodies.
D000818:Animals; D000918:Antibody Specificity; D000937:Antigen-Antibody Reactions; D001665:Binding Sites; D002470:Cell Survival / Q000187:drug effects; D002859:Chromium Isotopes; D003168:Complement Fixation Tests; D003165:Complement System Proteins; D003298:Coombs Test; D004195:Disease Models, Animal / Q000276:immunology; D004492:Edetic Acid / Q000494:pharmacology; D004912:Erythrocytes / Q000187:drug effects / Q000276:immunology*; D006168:Guinea Pigs; D006386:Hemagglutination Tests; D006461:Hemolysis; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D007136:Immunoglobulins / Q000378:metabolism; D007456:Iodine Isotopes; D008099:Liver / Q000276:immunology; D011817:Rabbits; D013997:Time Factors; D014688:Venoms / Q000494:pharmacology
D002859:Chromium Isotopes; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D007456:Iodine Isotopes; D014688:Venoms; D003165:Complement System Proteins; D004492:Edetic Acid